株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非侵襲性出生前診断市場分析:妊娠期間別 (0〜12週、13〜24週、25〜36週)、妊娠リスクレベル別 (高、平均、低)、地域別 (米国、英国、ドイツ、日本、中国、ブラジル) のセグメント予測

Non-Invasive Prenatal Testing Market Analysis by Gestation Period (0-12 weeks, 13-24 weeks, 25-36 weeks), by Pregnancy RiskLevel (High & Average Risk, Low Risk), By Region (U.S., UK, Germany, Japan, China, Brazil)And Segment Forecasts, 2014 - 2025

発行 Grand View Research, Inc. 商品コード 408973
出版日 ページ情報 英文 100 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.28円で換算しております。
Back to Top
非侵襲性出生前診断市場分析:妊娠期間別 (0〜12週、13〜24週、25〜36週)、妊娠リスクレベル別 (高、平均、低)、地域別 (米国、英国、ドイツ、日本、中国、ブラジル) のセグメント予測 Non-Invasive Prenatal Testing Market Analysis by Gestation Period (0-12 weeks, 13-24 weeks, 25-36 weeks), by Pregnancy RiskLevel (High & Average Risk, Low Risk), By Region (U.S., UK, Germany, Japan, China, Brazil)And Segment Forecasts, 2014 - 2025
出版日: 2016年12月02日 ページ情報: 英文 100 Pages
概要

当レポートでは、世界の非侵襲性出生前診断市場について調査し、市場の動向、妊娠期間別、妊娠リスクレベル別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 調査方法

第2章 エグゼクティブサマリー

第3章 市場の変動、動向、範囲

  • 市場セグメンテーションと範囲
    • 促進因子分析
    • 阻害因子分析
  • 浸透・成長見通しマッピング
  • SWOT分析:要因別
  • 業界分析:ポーターズ

第4章 妊娠期間別予測・動向分析

  • 妊娠期間別動向分析
  • 0〜12週
  • 25〜36週

第5章 リスクタイプ別予測・動向分析

  • リスクタイプ別動向分析
  • 高リスク・平均的リスク
  • 低リスク

第6章 地域別予測・動向分析

  • 地域別市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合環境

  • 戦略枠組み
  • 競合プロファイル
目次
Product Code: GVR-1-68038-310-2

The global non-invasive prenatal testing market is anticipated to reach USD 5.5 billion by 2025, according to a new report by Grand View Research, Inc. Evolution of prenatal testing in the form of noninvasive tests that can serve as an intermediate step between serum screening and invasive diagnostic testing to determine the likelihood of fetal abnormality is expected to drive growth in the reproductive genetics industry over the forecast period.

In addition, presence of payers such as Anthem and Blue Shield of California that have endorsed cfDNA-based Noninvasive Prenatal Testing (NIPT) for trisomies 13, 18, and 21 is expected to impact the adoption rate of these tests, thereby resulting in increased revenue generation.

However, the projected NIPT-related price erosion in this market is expected to continue, thus intensifying competition amongst the operating participants, but restraining revenue generation to a certain extent.

Further Key Findings fromthe Report Suggest:

  • The market is segmented on the basis of the tests carried out during the gestation period as 0-12 weeks, 13-24 weeks, and 25-36 weeks
  • 13-24 weeks accounted for the largest share owing to the presence of maximum number of the tests carried out in this phase of pregnancy
  • High & average risk pregnancy held the larger share owing to presence of favorable payer reimbursement in this segment
  • Rising awareness pertaining to the prevention and screening of chromosomal anomalies, such as Down Syndrome is another factor anticipated to impact adoption
  • Asia Pacific is expected to register fastest year-on-year progress owing to the gradually increasing average maternal age, & increasing incidence of chromosomal aneuploidies
  • Some of the key players operating the market space include Natera, Inc;Illumina, Inc; Sequenom; Roche (Ariosa Diagnostics); Quest Diagnostics; and LabCorp
  • One of the key trends followed by companies includes licensing of the test to other labs and generating significant revenue by collecting royalty payments

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Data Analysis

Chapter 2 Executive Summary

Chapter 3 NIPT Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Increasing average maternal age and rising incidence of chromosome syndromes
      • 3.1.1.2 Presence of demand for early and Non-Invasive fetal testing procedure
      • 3.1.1.3 Improvement in the reimbursement scenario
      • 3.1.1.4 Presence of collaborations and licensing agreements
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Price erosion of the NIPT products
      • 3.1.2.2 Ethical concerns with respect to reproductive genetics
  • 3.2 Penetration & Growth Prospect Mapping, 2015
  • 3.3 Non-Invasive prenatal testing - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 NIPT Market: Gestation Duration Estimates & Trend Analysis

  • 4.1 Non-Invasive Prenatal Testing: Gestation Duration Movement Analysis
  • 4.2 0-12 weeks
    • 4.2.1 Global NIPT 0-12 weeks, 2014 - 2025 (USD Million)
  • 4.3 13-24 weeks
    • 4.3.1 Global NIPT 13-24 weeks, 2014 - 2025 (USD Million)
  • 4.4 25-36 weeks
    • 4.4.1 Global NIPT 25-36 weeks, 2014 - 2025 (USD Million)

Chapter 5 NIPT Market: Risk Type Estimates & Trend Analysis

  • 5.1 Non-Invasive Prenatal Testing: Risk Type Movement Analysis
  • 5.2 High & Average Risk
    • 5.2.1 Global high & average risk NIPT market, 2013 - 2025 (USD Million)
  • 5.3 Low Risk
    • 5.3.1 Global low risk NIPT market, 2013 - 2025 (USD Million)

Chapter 6 NIPT Market: Regional Estimates & Trend Analysis, by Gestation Period & Risk Type

  • 6.1 Non-Invasive Prenatal Testing Share By Region, 2015 & 2025
  • 6.2 North America
    • 6.2.1 North America Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S Non-Invasive prenatal testing culture market, 2013 - 2025 (USD Million)
    • 6.2.3 Canada.
      • 6.2.3.1 Canada Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
    • 6.3.2 Germany.
      • 6.3.2.1 Germany Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
    • 6.3.3 UK
      • 6.3.3.1 UK Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • 6.4 Asia Pacific.
    • 6.4.1 Asia Pacific Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
    • 6.4.2 China
      • 6.4.2.1 China Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
    • 6.4.3 Japan
      • 6.4.3.1 Japan Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • 6.5 Latin America.
    • 6.5.1 Latin America Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • 6.6 Middle East & Africa.
    • 6.6.1 Middle East & Africa Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa Non-Invasive prenatal testing, 2013 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy framework
  • 7.2 Market participation categorization
    • 7.2.1 Natera Inc.
      • 7.2.1.1 Company overview
      • 7.2.1.2 Financial performance
      • 7.2.1.3 Product benchmarking
      • 7.2.1.4 Strategic initiatives
    • 7.2.2 Illumina Inc. (Verinata Health, Inc.)
      • 7.2.2.1 Company overview
      • 7.2.2.2 Financial performance
      • 7.2.2.3 Product benchmarking
      • 7.2.2.4 Strategic initiatives
    • 7.2.3 Sequenom Laboratories
      • 7.2.3.1 Company overview
      • 7.2.3.2 Financial performance
      • 7.2.3.3 Product benchmarking
      • 7.2.3.4 Strategic initiatives
    • 7.2.4 Laboratory Corporation of America Holdings
      • 7.2.4.1 Company overview
      • 7.2.4.1 Financial Performance
      • 7.2.4.2 Product benchmarking
      • 7.2.4.3 Strategic initiatives
    • 7.2.5 Quest Diagnostics
      • 7.2.5.1 Company overview
      • 7.2.5.2 Financial performance
      • 7.2.5.3 Product benchmarking
      • 7.2.5.4 Strategic initiatives
    • 7.2.6 F. Hoffmann-La Roche Ltd (Ariosa Diagnostics)
      • 7.2.6.1 Company overview
      • 7.2.6.2 Financial performance
      • 7.2.6.3 Product benchmarking
      • 7.2.6.4 Strategic initiatives
    • 7.2.7 BGI Diagnosis
      • 7.2.7.1 Company overview
      • 7.2.7.2 Financial performance
      • 7.2.7.3 Product benchmarking
      • 7.2.7.4 Strategic initiatives
    • 7.2.8 LifeCodexx AG
      • 7.2.8.1 Company overview
      • 7.2.8.2 Financial performance
      • 7.2.8.3 Product benchmarking
      • 7.2.8.4 Strategic initiatives
    • 7.2.9 Berry Genomics Co. Ltd.
      • 7.2.9.1 Company overview
      • 7.2.9.2 Financial performance
      • 7.2.9.3 Product benchmarking
      • 7.2.9.4 Strategic initiatives

List of Tables

  • TABLE 1 North America Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 2 North America Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 3 North America Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 4 North America Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 5 U.S. Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 6 U.S. Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 7 U.S. Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 8 U.S. Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 9 Canada Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 10 Canada Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 11 Canada Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 12 Canada Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 13 Europe Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 14 Europe Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 15 Europe Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 16 Europe Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 17 Germany Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 18 Germany Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 19 Germany Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 20 Germany Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 21 UK Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 22 UK Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 23 UK Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 24 UK Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 25 Asia Pacific Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 26 Asia Pacific Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 27 Asia Pacific Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 28 Asia Pacific Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 29 China Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 30 China Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 31 China Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 32 China Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 33 Japan Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 34 Japan Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 35 Japan Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 36 Japan Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 37 Latin America Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 38 Latin America Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 39 Latin America Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 40 Latin America Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 41 Brazil Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 42 Brazil Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 43 Brazil Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 44 Brazil Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 45 MEA Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 46 MEA Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 47 MEA Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 48 MEA Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
  • TABLE 49 South Africa Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
  • TABLE 50 South Africa Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
  • TABLE 51 South Africa Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
  • TABLE 52 South Africa Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 Penetration & growth prospect mapping, 2015
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Non-Invasive prenatal testing: Gestation duration outlook key takeaways
  • FIG. 16 Non-Invasive prenatal testing: Gestation duration movement analysis
  • FIG. 17 Global Non-Invasive prenatal testing in 0-12 weeks, 2014 - 2025 (USD Million)
  • FIG. 18 Global Non-Invasive prenatal testing in 13-24 weeks, 2014 - 2025 (USD Million)
  • FIG. 19 Global Non-Invasive prenatal testing in 25-36 weeks, 2014 - 2025 (USD Million)
  • FIG. 20 Non-Invasive prenatal testing: Risk type outlook key takeaways
  • FIG. 21 Global Non-Invasive prenatal testing: Risk type movement analysis
  • FIG. 22 Global high & average risk NIPT market, 2013 - 2025 (USD Million)
  • FIG. 23 Global low risk NIPT market, 2013 - 2025 (USD Million)
  • FIG. 24 Regional market place: Key takeaway
  • FIG. 25 Non-Invasive prenatal testing regional outlook, 2015 & 2024
  • FIG. 26 North America Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 27 U.S Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 28 Canada Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 29 Europe Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 30 Germany Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 31 UK Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 32 Asia Pacific Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 33 China Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 34 Japan Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 35 Latin America Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 36 Brazil Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 37 Middle East & Africa Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 38 South Africa Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
  • FIG. 39 Strategy framework
  • FIG. 40 Participant categorization
Back to Top